Oncotelic Therapeutics, Inc. (OTCMKTS:OTLC) Short Interest Down 69.2% in December

Oncotelic Therapeutics, Inc. (OTCMKTS:OTLC) was the target of a significant drop in short interest in the month of December. As of December 31st, there was short interest totaling 14,881 shares, a drop of 69.2% from the December 15th total of 48,369 shares. Based on an average daily volume of 216,984 shares, the days-to-cover ratio is presently 0.1 days. Approximately 0.0% of the shares of the stock are short sold. Approximately 0.0% of the shares of the stock are short sold. Based on an average daily volume of 216,984 shares, the days-to-cover ratio is presently 0.1 days.

Oncotelic Therapeutics Stock Performance

OTLC opened at $0.07 on Wednesday. Oncotelic Therapeutics has a twelve month low of $0.02 and a twelve month high of $0.11. The company has a 50-day moving average price of $0.09 and a 200 day moving average price of $0.07.

About Oncotelic Therapeutics

Oncotelic Therapeutics is a clinical‐stage biotechnology company dedicated to the development of novel oncolytic virotherapy and diagnostic platforms for cancer treatment. The company’s lead therapeutic candidate, telomelysin (OBP‐301), is an oncolytic adenovirus engineered to selectively replicate in telomerase‐positive tumor cells, offering a targeted approach to destroying cancerous tissue while sparing healthy cells. In addition to its therapeutic pipeline, Oncotelic markets TelomeScan, a proprietary diagnostic assay designed to detect and enumerate viable circulating tumor cells by exploiting telomerase activity.

Originally founded with technology licensed from Japanese research institutions, Oncotelic has established collaborative relationships in both the United States and Asia to advance its clinical and commercial programs.